Evaluation of one-year lamivudine and telbivudine therapy on chronic hepatitis b patients: Based on biochemical, virological and fibrosis status in dr. soetomo general hospital

Ummi Maimunah and S. A. Syalini and Iswan Abbas Nusi and Titong Sugihartono and Budi Widodo and Ulfa Kholili and Husin Thamrin and Amie Vidyani and Muhammad Miftahussurur and Poernomo Boedi Setiawan (2019) Evaluation of one-year lamivudine and telbivudine therapy on chronic hepatitis b patients: Based on biochemical, virological and fibrosis status in dr. soetomo general hospital. New Armenian Medical Journal, 13 (4). pp. 31-38. ISSN 18290825

[img] Text
Miftahussurur-Evaluation of one-year lamivudine.pdf

Download (49kB)
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

Background: Lamivudine and telbivudine are still the recommended treatment for hepatitis B, especially in Indonesia. However, no conclusive results on evaluation of the lamivudine and telbivudine therapy in Dr. Soetomo hospital in one-year therapy. Objective: To evaluate one-year Lamivudine and Telbivudine based on Hepatitis B Virus DNA, alanine aminotransferase, aspartat aminotransferase to platelet ratio index score, fibrosis-4, raid plasma reagin, platelet to lymphocite ratio score, transient elastography and liver biopsy. Methods: This is analytic observational study and carried out by evaluating secondary data from medical record in Dr. Soetomo hospital. Results: Significant decreased of Hepatitis B Virus DNA, normalization of alanine aminotransferase, improvement of aspartat aminotransferase to platelet ratio index, PLR and Transient elastography in one year each of lamivudine (p = 0.00; p=0.00; p = 0.00; p = 0.00; p = 0.00) and telbivudine group (p = 0.00; p=0.00; p = 0.00; p = 0.00; p =0.00). In HbeAg negative and positive patients, there were no significant different between lamivudine and telbivudine based on Hepatitis B Virus DNA reduction, normalization of alanine aminotransferase, improvement of aspartat aminotransferase to platelet ratio index score, fibrosis-4, platelet ratio index, transient elastography and liver biopsy. However, there was significant difference between lamivudine and telbivudine based on raid plasma reagin score in HBeAg positive patient (p = 0.013). Conclusion: There were no significant difference between lamivudine and telbivudine oneyear therapy based on biochemical, virological, and fibrosis status in Dr. Soetomo hospital. © 2019, Yerevan State Medical University. All rights reserved.

Item Type: Article
Uncontrolled Keywords: Chronic hepatitis B, Lamivudine, Telbivudine
Subjects: R Medicine
R Medicine > R Medicine (General)
R Medicine > R Medicine (General) > R735-854 Medical education. Medical schools. Research
Divisions: Artikel Ilmiah > SCOPUS INDEXED JOURNAL
Creators:
CreatorsNIM
Ummi MaimunahNIDN8896900016
S. A. SyaliniUNSPECIFIED
Iswan Abbas NusiNIDN0028025003
Titong SugihartonoNIDN8836800016
Budi WidodoNIDN8804800016
Ulfa KholiliNIDN0004047511
Husin ThamrinNIDN8825800016
Amie VidyaniNIDN0028018002
Muhammad MiftahussururNIDN0029097909
Poernomo Boedi SetiawanNIDN8886900016
Depositing User: PPJPI
Date Deposited: 28 Sep 2020 03:40
Last Modified: 28 Sep 2020 03:40
URI: http://repository.unair.ac.id/id/eprint/94580
Sosial Share:

Actions (login required)

View Item View Item